CV Sciences (0HRT) AI Stock Analysis
Top Page
CV Sciences
(LSE:0HRT)
No summary available
CV Sciences (0HRT) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $2.26M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- -0.39
- Revenue Growth
- -14.90%
- EPS Growth
- -22.35%
- Country
- UK
- Employees
- 43
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
CV Sciences Business Overview & Revenue Model
Company Description
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division fo...
CV Sciences Earnings Call Summary
The call presented a balanced picture: the company is making meaningful progress on cost reductions, working capital management and product/brand expansion (including a growing non‑cannabinoid line and DTC efforts) and has achieved modest positive operating cash flow. However, material top-line pressure (revenue down 7% QoQ and 17% YoY; unit sales down 15%), widening GAAP net loss ($0.8M) and a low cash balance (~$0.3M) are significant headwinds. Regulatory uncertainty remains an important risk. Overall, positives (cost discipline, product launches, near cash‑flow breakeven) are counterbalanced by substantial revenue and liquidity challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that the company will prioritize scaling and profitable growth by expanding non‑cannabinoid +PlusHLTH product launches and select international expansion via Cultured Foods while continuing strict cost and working‑capital discipline to drive margins and cash flow. Key metrics referenced: Q2 revenue of $3.0M (down 7% sequential, 17% YoY; unit sales down 15%), gross margin 48.6% (48.9% in Q1; 50.9% year‑ago), SG&A $1.7M (down ~7.9% sequential/~10% YoY), adjusted EBITDA loss $0.1M (flat vs Q1), operating loss $0.3M, net loss $0.8M, positive operating cash flow of ~ $20k in Q2 (also positive in Q1), cash ≈ $0.3M, inventory ≈ $4.0M (vs $4.1M year‑end), and convertible note fair value $1.0M after ~ $0.7M of conversions — with an aim to reach sustainable positive operating cash flow and to remain flexible pending regulatory timing changes (potential delay of Nov 12, 2026 provisions to Dec 11, 2026).
CV Sciences Peers Comparison
Overall Rating
IXHL52Neutral
YCBD46Neutral
IMCC38Underperform
COSM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IXHL | 52Neutral | $31.61M | -2.25 | -18.27% | ― | -100.00% | 95.90% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| YCBD | 46Neutral | $4.29M | -1.25 | -34.25% | ― | 10.01% | 95.01% |
| IMCC | 38Underperform | $1.30M | -0.03 | 841.81% | ― | -11.91% | -285.26% |
| COSM | 37Underperform | $30.99M | -0.47 | -118.89% | ― | 33.82% | 34.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0HRT | CV Sciences | 0.02 | -0.03 | -60.00% | |
| YCBD | Cbdmd INc | 0.38 | -0.46 | -54.52% | |
| COSM | Cosmos Holdings | 0.31 | -0.47 | -60.39% | |
| IMCC | Im Cannabis Corp | 0.79 | -40.91 | -98.10% | |
| IXHL | Incannex Healthcare Limited Sponsored ADR | 2.52 | -8.10 | -76.27% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.